Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. more
Time Frame | ARTL | Sector | S&P500 |
---|---|---|---|
1-Week Return | - | -1.8% | -0.77% |
1-Month Return | -11.08% | -3.48% | 0.71% |
3-Month Return | -7.56% | -7.2% | 8.81% |
6-Month Return | -20% | -1.54% | 12.32% |
1-Year Return | -22.54% | 8.39% | 30.57% |
3-Year Return | -87.71% | 6.07% | 29.21% |
5-Year Return | -96.67% | 44.07% | 91.95% |
10-Year Return | -98.17% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 3.21M | 4.69M | 7.44M | 10.29M | 9.93M | [{"date":"2019-12-31","value":31.2,"profit":true},{"date":"2020-12-31","value":45.55,"profit":true},{"date":"2021-12-31","value":72.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.53,"profit":true}] |
Operating Income | (3.21M) | (4.69M) | (7.44M) | (10.29M) | (9.93M) | [{"date":"2019-12-31","value":-320953100,"profit":false},{"date":"2020-12-31","value":-468577500,"profit":false},{"date":"2021-12-31","value":-744100000,"profit":false},{"date":"2022-12-31","value":-1028700000,"profit":false},{"date":"2023-12-31","value":-993000000,"profit":false}] |
Total Non-Operating Income/Expense | - | 31.91K | 4.00K | 200.00K | 641.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":4.98,"profit":true},{"date":"2021-12-31","value":0.62,"profit":true},{"date":"2022-12-31","value":31.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (2.17M) | (4.65M) | (7.44M) | (10.08M) | (9.29M) | [{"date":"2019-12-31","value":-217217600,"profit":false},{"date":"2020-12-31","value":-465486200,"profit":false},{"date":"2021-12-31","value":-743700000,"profit":false},{"date":"2022-12-31","value":-1008300000,"profit":false},{"date":"2023-12-31","value":-928900000,"profit":false}] |
Income Taxes | (2.04M) | (60.41K) | (4.00K) | (209.00K) | - | [{"date":"2019-12-31","value":-204345400,"profit":false},{"date":"2020-12-31","value":-6041400,"profit":false},{"date":"2021-12-31","value":-400000,"profit":false},{"date":"2022-12-31","value":-20900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (4.59M) | (7.43M) | (9.87M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-459444800,"profit":false},{"date":"2021-12-31","value":-743300000,"profit":false},{"date":"2022-12-31","value":-987400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (2.17M) | (4.65M) | (7.44M) | (10.29M) | (9.29M) | [{"date":"2019-12-31","value":-217217600,"profit":false},{"date":"2020-12-31","value":-465486200,"profit":false},{"date":"2021-12-31","value":-743700000,"profit":false},{"date":"2022-12-31","value":-1028600000,"profit":false},{"date":"2023-12-31","value":-928900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.17M) | (4.65M) | (7.44M) | (9.87M) | (9.29M) | [{"date":"2019-12-31","value":-217217600,"profit":false},{"date":"2020-12-31","value":-465486200,"profit":false},{"date":"2021-12-31","value":-743700000,"profit":false},{"date":"2022-12-31","value":-987400000,"profit":false},{"date":"2023-12-31","value":-928900000,"profit":false}] |
EPS (Diluted) | (29.94) | (15.15) | (3.55) | - | (5.66) | [{"date":"2019-12-31","value":-2993.96,"profit":false},{"date":"2020-12-31","value":-1515,"profit":false},{"date":"2021-12-31","value":-355.38,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-566,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ARTL | |
---|---|
Current Ratio | 7.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ARTL | |
---|---|
ROA (LTM) | -54.33% |
ROE (LTM) | -88.58% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ARTL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ARTL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.56 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 1.22 |
Artelo Biosciences Inc (ARTL) share price today is $1.1
Yes, Indians can buy shares of Artelo Biosciences Inc (ARTL) on Vested. To buy Artelo Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARTL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Artelo Biosciences Inc (ARTL) via the Vested app. You can start investing in Artelo Biosciences Inc (ARTL) with a minimum investment of $1.
You can invest in shares of Artelo Biosciences Inc (ARTL) via Vested in three simple steps:
The 52-week high price of Artelo Biosciences Inc (ARTL) is $1.75. The 52-week low price of Artelo Biosciences Inc (ARTL) is $1.
The price-to-earnings (P/E) ratio of Artelo Biosciences Inc (ARTL) is
The price-to-book (P/B) ratio of Artelo Biosciences Inc (ARTL) is 0.56
The dividend yield of Artelo Biosciences Inc (ARTL) is 0.00%
The market capitalization of Artelo Biosciences Inc (ARTL) is $3.58M
The stock symbol (or ticker) of Artelo Biosciences Inc is ARTL